These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9552583)

  • 21. [Diagnosis of thrombophilia based on coagulation and genetic studies].
    Bałszan-Kowalska I
    Ann Acad Med Stetin; 2002; 48():179-93. PubMed ID: 14601477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Activated protein C resistance--a recently discovered hereditary thrombophilia].
    Moland L; Sandset PM
    Tidsskr Nor Laegeforen; 1998 Sep; 118(23):3590-5. PubMed ID: 9820002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activated protein C resistance and factor V Leiden in Mexico.
    Majluf-Cruz A; Moreno-Hernández M; Ruiz-de-Chávez-Ochoa A; Monroy-García R; Majluf-Cruz K; Guardado-Mendoza R; Molina-Avila I; Isordia-Salas I; Corona-de la Peña N; Vargas-Vorackova F; Vela-Ojeda J; García-Chávez J
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):428-37. PubMed ID: 18160617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of modified functional assays for activated protein C resistance in patients with basally prolonged aPTT.
    Montaruli B; Schinco P; Pannocchia A; Giorgianni A; Borchiellini A; Tamponi G; Pileri A
    Thromb Haemost; 1997 Sep; 78(3):1042-8. PubMed ID: 9308751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activated protein C resistance -- in the absence of factor V Leiden -- and pregnancy.
    Lindqvist PG; Svensson P; Dahlbäck B
    J Thromb Haemost; 2006 Feb; 4(2):361-6. PubMed ID: 16420566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Activated protein C resistance: role in venous and arterial thrombosis].
    Emmerich J; Alhenc-Gelas M; Aiach M; Fiessinger JN
    Arch Mal Coeur Vaiss; 1996 Jun; 89(6):741-5. PubMed ID: 8760661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
    Graf LL; Welsh CH; Qamar Z; Marlar RA
    Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inherited activated protein C resistance in a patient with familial primary antiphospholipid syndrome.
    Alarcón-Segovia D; Ruiz-Argüelles GJ; Garcés-Eisele J; Ruiz-Argüelles A
    J Rheumatol; 1996 Dec; 23(12):2162-5. PubMed ID: 8970058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activated protein C resistance--a major risk factor for thrombosis.
    Rosén SB; Sturk A
    Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful liver transplantation in a patient with Budd-Chiari syndrome caused by homozygous factor V Leiden.
    Tan HP; Markowitz JS; Maley WR; Merritt WT; Klein AS
    Liver Transpl; 2000 Sep; 6(5):654-6. PubMed ID: 10980068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. APCR, factor V gene known and novel SNPs and adverse pregnancy outcomes in an Irish cohort of pregnant women.
    Sedano-Balbás S; Lyons M; Cleary B; Murray M; Gaffney G; Maher M
    BMC Pregnancy Childbirth; 2010 Mar; 10():11. PubMed ID: 20214832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between the functional assay for activated protein C resistance and factor V Leiden in the neonate.
    Sifontes MT; Nuss R; Hunger SP; Jacobson LJ; Waters J; Manco-Johnson MJ
    Pediatr Res; 1997 Dec; 42(6):776-8. PubMed ID: 9396556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza Thrombophilia and Atherosclerosis.
    Tosetto A; Missiaglia E; Gatto E; Rodeghiero F
    Thromb Haemost; 1997 Aug; 78(2):859-63. PubMed ID: 9268185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of phenotypic activated protein C resistance (APCR) in venous thromboembolic patients.
    Marzo C; Araguás C; Gómez-Arbonés J; Ramírez S
    Haematologica; 1998 Apr; 83(4):377-8. PubMed ID: 9592990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obstetric implications of the factor V leiden mutation: a review.
    Bloomenthal D; Delisle MF; Tessier F; Tsang P
    Am J Perinatol; 2002 Jan; 19(1):37-47. PubMed ID: 11857095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary thrombophilia in Saudi Arabia.
    Al-Jaouni SK
    Saudi Med J; 2003 Jun; 24(6):614-6. PubMed ID: 12847589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.
    Zöller B; Svensson PJ; He X; Dahlbäck B
    J Clin Invest; 1994 Dec; 94(6):2521-4. PubMed ID: 7989612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis.
    de Visser MC; Guasch JF; Kamphuisen PW; Vos HL; Rosendaal FR; Bertina RM
    Thromb Haemost; 2000 Apr; 83(4):577-82. PubMed ID: 10780320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers.
    Mingozzi F; Legnani C; Lunghi B; Scanavini D; Castoldi E; Palareti G; Marchetti G; Bernardi F
    Thromb Haemost; 2003 Jun; 89(6):983-9. PubMed ID: 12783110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden.
    Lincz LF; Lonergan A; Scorgie FE; Rowlings P; Gibson R; Lawrie A; Seldon M
    Pathophysiol Haemost Thromb; 2006; 35(6):435-9. PubMed ID: 17565236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.